Summit Therapeutics (SMMT) Q1 2025 earnings summary

Executive summary

• Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, advanced through multiple Phase III trials, including global studies and collaborations with Akeso, MD Anderson, and Pfizer, with topline HARMONI results expected mid-2025.

• Ivonescimab received regulatory approval in China as frontline monotherapy for NSCLC with positive PD-L1 expression, based on Harmony-II trial results and demonstrated significant PFS and OS benefits.

• Preparations for commercial launch are underway, including key leadership hires and manufacturing scale-up.

• Expanded Akeso license in June 2024 to cover Latin America, Middle East, and Africa, with significant milestone and royalty obligations.

Financial highlights

• Cash and short-term investments totaled $361.3 million as of March 31, 2025, with no debt outstanding.

• Q1 2025 GAAP net loss was $62.9 million ($0.09/share), up from $43.5 million in Q1 2024; non-GAAP net loss was $51.8 million ($0.07/share).

• GAAP R&D expenses were $51.2 million in Q1 2025, flat sequentially but up year-over-year; non-GAAP R&D expenses were $47.1 million.

• GAAP G&A expenses increased to $15.6 million in Q1 2025, mainly due to higher professional services and compensation.

• Net cash used in operating activities was $61.1 million for Q1 2025.

Outlook and guidance

• Topline data from the global HARMONI Phase III trial in EGFR-mutated advanced NSCLC expected mid-2025.

• Additional clinical trial initiations, data readouts, and pipeline expansion announcements anticipated in 2025.

• Sufficient cash and investments to fund operations for at least the next 12 months; additional capital may be needed for milestone payments and future operations.